Gilead Sciences (GILD) News Today → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free Gild Stock Alerts $64.27 +0.19 (+0.30%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 9:00 AM | businesswire.comZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated ComputingJune 2 at 8:00 AM | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 2 at 8:00 AM | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 2 at 2:22 AM | americanbankingnews.comGilead Sciences (NASDAQ:GILD) Shares Gap Down to $64.08June 1 at 2:19 PM | marketbeat.comBank of Nova Scotia Buys 130,552 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Bank of Nova Scotia boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 427,751 shares of the biopharmaceutical company's stock after buying an additional 13June 1 at 8:00 AM | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersJune 1 at 8:00 AM | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersJune 1 at 2:44 AM | americanbankingnews.comGilead Sciences, Inc. (NASDAQ:GILD) Receives $83.69 Consensus Target Price from BrokeragesMay 31 at 2:59 PM | marketbeat.comParnassus Investments LLC Has $968.24 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Parnassus Investments LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 11,952,057 shares of the biopharmaceutical company's stock after purchasing an additional 36,686May 31 at 11:14 AM | benzinga.comGilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder CancerMay 31 at 8:09 AM | reuters.comGilead's Trodelvy extends lung cancer survival by just 1.3 months in trialMay 31 at 8:07 AM | businesswire.comEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024May 30 at 5:04 PM | reuters.comGilead's Trodelvy fails to meet main goal in late-stage studyMay 30 at 4:45 PM | businesswire.comGilead Provides Update on Phase 3 TROPiCS-04 StudyMay 30 at 9:22 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by TD Asset Management IncTD Asset Management Inc lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,029,657 shares of the biopharmaceutical cMay 29, 2024 | marketbeat.comTFO Wealth Partners LLC Acquires 16,006 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)TFO Wealth Partners LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 29,640.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,060 shares of the biopharmaceuticaMay 29, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Rating of "Hold" from AnalystsGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) has been assigned an average rating of "Hold" from the seventeen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Eleven research analysts have rated the stock with a hold recommendation and six have assigned a bMay 28, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Reaches New 52-Week Low at $64.19Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month Low at $64.19May 28, 2024 | seekingalpha.comGilead Sciences: Seriously Undervalued At Peak PessimismMay 28, 2024 | finance.yahoo.comGilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"May 28, 2024 | fool.com2 Beaten-Down Dividend Stocks to Buy and Hold For 10 YearsMay 28, 2024 | businesswire.comCartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target PairsMay 27, 2024 | marketbeat.comUnited Services Automobile Association Buys 90,194 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)United Services Automobile Association lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 67.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 222,985 shares of the biopharmaMay 27, 2024 | seekingalpha.comUnloved Gilead Due For Reversal On Flight-To-Safety Money FlowsMay 27, 2024 | seekingalpha.comUnloved Gilead Due For Reversal On Flight-To-Safety Money FlowsMay 26, 2024 | marketbeat.comIntech Investment Management LLC Sells 141,024 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Intech Investment Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 373,106 sharesMay 25, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Advisory Services Network LLCAdvisory Services Network LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 75,434 shares of the biopharmaceutical company's stock after sellMay 24, 2024 | marketbeat.comNomura Asset Management Co. Ltd. Purchases 14,557 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Nomura Asset Management Co. Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 906,670 shares of the biopharmaceutical company's stock after purchaMay 24, 2024 | barrons.comCancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.May 24, 2024 | marketbeat.comGreylin Investment Management Inc Sells 32,265 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Greylin Investment Management Inc cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 64,368 shares of the biopharmaceutical company'May 23, 2024 | seekingalpha.comWhy Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart InvestorsMay 22, 2024 | marketbeat.comOntario Teachers Pension Plan Board Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD)Ontario Teachers Pension Plan Board trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,446 sharesMay 22, 2024 | investorplace.com3 Biotech Stocks to Buy Now: May 2024May 22, 2024 | businesswire.comGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024May 21, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Dai ichi Life Insurance Company LtdDai ichi Life Insurance Company Ltd decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 56.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 329,283 shares of the biopharmaceutical company's stock after selling 431,May 21, 2024 | finance.yahoo.comGilead Sciences Hosts Inaugural Global Health Equity SummitMay 20, 2024 | marketbeat.com21,827 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Simplicity Wealth LLCSimplicity Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,827 shares of the biopharmaceutical company's stock, valued at approximately $1,599,000. SMay 20, 2024 | markets.businessinsider.comSeladelpar’s Efficacy in PBC and Strategic Acquisition by Gilead Prompt Buy RatingMay 20, 2024 | finance.yahoo.comGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated ItchMay 19, 2024 | marketbeat.comING Groep NV Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)ING Groep NV increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 931,968 shares of the biopharmaceutical company's stock after acquiring anMay 18, 2024 | markets.businessinsider.comGilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC StudyMay 18, 2024 | marketbeat.comMeridian Wealth Management LLC Has $3.31 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Meridian Wealth Management LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 77.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,807 shares of the biopharmaceuMay 18, 2024 | businesswire.comInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisMay 16, 2024 | marketbeat.comARGA Investment Management LP Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)ARGA Investment Management LP boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 635,058 shares of theMay 16, 2024 | marketbeat.comGilead Sciences Q1 Earnings TranscriptMay 15, 2024 | benzinga.comMarket Whales and Their Recent Bets on GILD OptionsMay 15, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)May 14, 2024 | seekingalpha.comGilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)May 14, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Mitsubishi UFJ Asset Management Co. Ltd.Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,316,128 shares oMay 14, 2024 | businesswire.comKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. GILD Media Mentions By Week GILD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.320.76▲Average Medical News Sentiment GILD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼2716▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRNA News Today SGEN News Today TECH News Today QGEN News Today CRSP News Today DNLI News Today AMGN News Today VRTX News Today REGN News Today BIIB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.